Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

Detailed price information for Cognition Therapeutics Inc (CGTX-Q) from The Globe and Mail including charting and trades.